Novavax not expected to seek authorization for experimental coronavirus vaccine until June at the earliest

“It may seem like Novavax is taking a long time to get through their development, but the benchmarks have been set from vaccines that have moved very, very fast,” said Rajeev Venkayya, president of the Global Vaccine Business Unit at Takeda Pharmaceutical, which has partnered with Novavax and plans to manufacture 250 million doses a year in Japan. “When it comes to developing tests for biological materials, that can be very complicated and can lead to long timelines in vaccine development.”